The Skinny Label And The New Biosimilar Surge

Medical Patents Broker Inc.
By Kenneth Pearce, President

The FDA’s 2026 Guidance

The FDA issued a new draft guidance that fundamentally changes the biosimilar playing field. Generally, biosimilar developers (the “generics” of the biologic world) were held back by the massive cost of clinical trials—often spending $20 million or more to prove the generic was biosimilar to the original. The legal moat protecting the original has become wadable.

The Newer Way:

• Streamlined Testing: The FDA has eliminated the default requirement for a "three-way" comparative study.
• The Cost Cut: This single change can save a competitor up to 50% of their study costs.
• The Result: The barrier to entry for biosimilars has decreased by millions of dollars.

The Expiration Wave: 2026–2030

Original biologic manufacturers generally file a plethora of patent applications related to their high-net biologics. These include:

1. The structure of the biologic.
2. The process of manufacturing.
3. The delivery device used to treat the patient.

Each of these classifications usually has a different expiration date. When the biologic does not have total “blanket coverage,” there is a seam for a generic manufacturer to slip through and secure a portion of the original invention's market share—often referred to as a “Skinny Label.”

MPB Reminder

Under Hatch-Waxman, the request for the Patent Term Extension (PTE) must be filed within sixty days of the FDA’s certification for use in commerce. Miss this deadline, and there is no appeal and no extension. The “legal monopoly” expires on date certain.

The President’s Viewpoint

The new 2026 FDA Guidance is a regulatory maneuver to neutralize the playing field. It gives the generic manufacturer the possibility of grabbing a portion of the original’s market share while making the endgame more cost-effective for the patient, which is also a good thing for Medicare and Medicaid.

Generally, an exit for one is an entry for another. Most original entrants expect an exit strategy that could include a license deal with a generic manufacturer. Whether you are the innovator defending your turf or the entrant looking for the "seam," MPB is positioned to orchestrate the transfer to the next level.